Angioedema is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Angioedema have a 85.71% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Angioedema compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Angioedema overview
Angioedema, characterized by non-pitting edema affecting various tissues, can become life-threatening when involving the larynx. Hereditary angioedema, often caused by C1-inhibitor gene mutations, necessitates early treatment to avoid airway complications. Histaminergic angioedema responds to antihistamines, corticosteroids, and epinephrine, while bradykinin-mediated angioedema, resistant to standard therapies, requires specialized approaches like C1 Inhibitor concentrate or icatibant. Treatment modalities also include short-term and long-term prophylaxis, addressing underlying triggers. Special considerations involve pregnancy, pediatric doses, and concurrent medication monitoring. Ongoing research explores options like recombinant human C1 esterase inhibitor and omalizumab for specific cases of angioedema, emphasizing tailored therapeutic strategies.
For a complete picture of PTSR and LoA scores for drugs in Angioedema, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
